Project name: Targeted and Improved Alzheimer’s Disease Drug Development
Support provider: Technology Agency of the Czech Republic KAPPA Programme
Funded: EEA grants – Norway grants
Project duration: January 2021 – April 2024
Main investigator: University hospital Hradec Kralove, Czech Republic – Assoc. Prof. Ondrej Soukup, Ph.D.
Other investigators: University of Oslo – Prof. Dr. med. Dr. rer. nat. Jens Pahnke E.F.N.
Institute of Experimental Medicine CAS – Martin Horak, Ph.D.
Bioinova, s.r.o. – Peter Bauer, M.D., Ph.D.
Contact persons: Ing. Zuzana Kodymova, Ing. Leona Markova
The aim of the project is the development of compounds for the treatment of Alzheimer´s disease (AD). The project will include an approaches of personalized medicine during the development process in the way that novel compounds will be tested in a disease in a dish (DiD) model derived from AD patients.